Vitamin D May Boost Breast Cancer Treatment Success by Up to 79%

A new study from Brazil suggests that low-dose vitamin D supplementation may significantly improve the effectiveness of chemotherapy in women with breast cancer. The research, conducted at the Botucatu School of Medicine at São Paulo State University (FMB-UNESP), found that women who took daily vitamin D alongside neoadjuvant chemotherapy were far more likely to see their tumors disappear before surgery compared to those who did not take the supplement.

Study Design and Key Findings

The clinical trial involved 80 women over the age of 45 who were preparing to begin treatment at the oncology outpatient clinic of the Hospital das Clínicas at FMB-UNESP. Participants were randomly divided into two groups: one received a daily dose of 2,000 international units (IU) of vitamin D, while the other received a placebo. All women underwent neoadjuvant chemotherapy, a standard treatment given before surgery to shrink tumors and improve surgical outcomes.

After six months of treatment, researchers observed a striking difference in tumor response between the two groups. Among women who took vitamin D, 43% experienced complete tumor disappearance following chemotherapy, compared to just 24% in the placebo group. This represents a 79% relative improvement in treatment success for those receiving the supplement.

Vitamin D’s Potential Role in Cancer Treatment

Vitamin D is best known for its role in bone health, helping the body absorb calcium, and phosphorus. However, emerging research has highlighted its broader biological functions, including immune system regulation. Many cancer patients are deficient in vitamin D, and previous studies have suggested that the vitamin may play a role in cancer prevention and treatment.

The study’s authors emphasize that the dosage used in the trial—2,000 IU per day—is relatively low compared to the higher doses often prescribed to correct vitamin D deficiency (typically 50,000 IU per week). This suggests that even modest supplementation could have meaningful benefits for chemotherapy patients.

Eduardo Carvalho-Pessoa, president of the São Paulo Regional Brazilian Society of Mastology and one of the study’s authors, noted the significance of the findings despite the small sample size. The dosage used in the research is far below the target dose for correcting vitamin D deficiency, yet we still observed a significant difference in chemotherapy response, he said. The results were published in the journal Nutrition and Cancer.

Implications for Breast Cancer Treatment

The study’s findings raise the possibility that vitamin D could serve as a simple, affordable adjunct to chemotherapy, particularly in settings where access to more expensive or specialized drugs is limited. Neoadjuvant chemotherapy is commonly used to reduce tumor size before surgery, and improving its effectiveness could lead to better surgical outcomes and potentially higher survival rates.

However, the researchers caution that further investigation is needed. The study’s relatively small sample size and short duration mean that larger, longer-term trials will be necessary to confirm these results and determine the optimal dosage and timing of vitamin D supplementation in cancer treatment.

The study was funded by the São Paulo Research Foundation (FAPESP), a public institution that supports scientific research in the state of São Paulo, Brazil. The findings add to a growing body of evidence suggesting that vitamin D may play a supportive role in cancer care, though it is not yet considered a standard part of treatment protocols.

Broader Context and Future Research

Breast cancer remains one of the most common cancers worldwide, and improving treatment outcomes is a major focus of ongoing research. While targeted therapies and immunotherapies have advanced significantly in recent years, many patients still rely on chemotherapy as a primary treatment. The potential for a low-cost, widely available supplement like vitamin D to enhance chemotherapy’s effectiveness could have significant implications for global cancer care, particularly in low-resource settings.

Future studies will need to explore whether these findings apply to other types of cancer and whether vitamin D supplementation could benefit patients undergoing different treatment regimens. Researchers will investigate the biological mechanisms behind vitamin D’s apparent synergy with chemotherapy, including its effects on immune function and tumor microenvironments.

For now, the study’s authors emphasize that patients should not self-prescribe vitamin D supplements without medical supervision. While the findings are promising, they represent early-stage research, and more evidence is needed before vitamin D can be recommended as a standard part of breast cancer treatment.

The research underscores the importance of addressing nutritional deficiencies in cancer patients, as these can impact treatment efficacy and overall health. As the scientific community continues to explore the connections between nutrition, immunity, and cancer, studies like this one may pave the way for more integrated approaches to cancer care.